Tegoprazan vs PPIs: Safety Outcomes in Post-PCI Patients

Theme

Cardiovascular Safety Meets Gastroprotection

Source
Source: Lee J, et al. Clinical Outcomes of Tegoprazan Versus Proton Pump Inhibitors in Patients Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention: A Retrospective, Observational Study. Korean J Helicobacter Up Gastrointest Res. 2026 Jan 20 [Epub ahead of print].

Tegoprazan Validated as a Viable First-Line Alternative to PPIs for Post-PCI Patients

Study Cohort

604 Patients
Ischemic Heart Disease (Post-PCI)

Comparison

Tegoprazan (50mg)
vs. Low-dose PPIs

Follow-Up

17 Months
Mean Duration

Superior Safety
0.4%
GI Event Rate

Incidence of symptomatic ulcers or bleeding with Tegoprazan vs. 1.8% with PPIs.

Zero cases of overt GI bleeding.

Incidence Rates: Tegoprazan vs. PPIs

Key Clinical Findings

Cardiac Safety (MACE)

Major Adverse Cardiac Events occurred in only 1.1% of the Tegoprazan group compared to 2.7% in the PPI group, dispelling drug-drug interaction concerns.

Myocardial Infarction

Rate of nonfatal MI was 3x lower with Tegoprazan (0.8%) vs PPIs (2.4%), favoring Tegoprazan for continuous antiplatelet therapy.

Recommendation: Adopt as First-Line Gastroprotective Agent

Tegoprazan effectively manages GI risks without compromising cardiovascular outcomes or interfering with clopidogrel metabolism. It should be considered a primary therapeutic option for high-risk patients requiring long-term antiplatelet therapy.

AbbreviationsQuick
ADP, adenosine diphosphate; CI, confidence interval; CV, cardiovascular; GI, gastrointestinal; HR, hazard ratio; IHD, ischemic heart disease; MACE, major adverse cardiac event; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug; P-CAB, potassium-competitive acid blocker; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor.
Bibliography1
  1. Lee J, Park J, Park J, et al. Clinical Outcomes of Tegoprazan Versus Proton Pump Inhibitors in Patients Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention: A Retrospective, Observational Study. Korean J Helicobacter Up Gastrointest Res. 2026 Jan 20 [Epub ahead of print]. (DOI: 10.7704/kjhugr.2025.0065 | link)
👀 View Mode